Robert A. Licht

Bob Licht is an experienced business attorney focusing on corporate and transactional work for life sciences companies. This includes representing biotechnology and other companies in structuring and negotiating strategic transactions, including joint ventures, collaborations and intellectual property licenses, and the full panoply of agreements that biopharmaceutical companies utilize to achieve strategic business objectives.


Prior to joining Choate, Bob spent more than 25 years as an in-house counsel. Most recently, Bob served as Senior Vice President, Chief Corporation Counsel, at Biogen, Inc.. During his eight years at Biogen, Bob was a key member of the executive leadership team where he managed the legal group responsible for supporting corporate governance, securities law compliance and disclosure, finance (including tax and treasury functions).

Practice Focus

Technology Transactions & Licensing: represents biotechnology and other life sciences companies in structuring and negotiating strategic transactions, including joint ventures, collaborations and intellectual property licenses. Experienced in representing both licensors and licensees in transactions spanning the research, development and commercialization of biopharmaceutical products, diagnostic products and medical devices.

Corporate: advises clients on various corporate matters, including contracts associated with the research, development, manufacture and commercialization of biopharmaceutical products, diagnostic products and medical devices, securities law compliance, and financing and M&A transactions.

Corporate Governance: advises boards of directors and senior management teams on sensitive corporate governance and disclosure issues.

Representative Transactions

  • Represented an intellectual property commercialization company and its subsidiaries in licensing innovative and foundational technology from a broad range of universities and a large pharmaceutical company.
  • Represented a small engineering company in negotiating a licensing agreement with a large pharmaceutical company for cell transplant enabling technology.
  • Represented a large pharmaceutical company in licensing several programs in oncology from another large pharmaceutical company.
  • Represented a pre-commercial biotechnology company in licensing ex-US rights to its lead compound.
  • Support for structuring, negotiating and closing a broad range of financing, collaboration and licensing and acquisition transactions, including collaboration agreement for lead Alzheimer’s disease drug candidate, $3 billion Dutch auction share repurchase, $1 billion senior unsecured public debt offering, and monetization of royalty stream from intellectual property license for marketed lupus medication.
  • $3.2 billion acquisition of collaborator’s interest in a multiple sclerosis drug development and commercialization collaboration.

Publications

  • “Current Issues in University and Research Institution Licensing Agreements,” moderator, Boston Bar Association Life Sciences Conference, September 2018.
  • “Client Law Firm Relationships,” panelist, MCLE, Boston, December 2013.
  • “Corporate Venture Capital Investing,” panelist, ACC-Northeast, Waltham, May 2011.
  • “Managing In-House Legal Departments,” panelist, FMI Legal Conference, San Diego, June 2006.
  • “Corporate Controls and Antitrust," presenter, FMI Convention, June 2005.

Professional and Community Involvement

Bob serves as a Volunteer Mediator in Woburn District Court.

He has also been a Pan-Mass Challenge Cyclist since 1994 and has raised more than $250,000 to benefit the Dana-Farber Cancer Institute.

Bob is past president of Lexington Youth Soccer and has served as a United States Soccer Federation Referee since 1999.

Education & Credentials

Harvard Law School
JD, magna cum laude, 1978

Editor, Harvard Law Review

Cornell University
BA, with distinction, 1975